Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia

Sarah A. Eisenstein, Ryan Bogdan, Ling Chen, Stephen M. Moerlein, Kevin J. Black, Joel S. Perlmutter, Tamara Hershey, Deanna M. Barch

Article history:
Received 19 July 2016
Received in revised form 7 October 2016
Accepted 15 November 2016

Keywords:
Schizophrenia
Negative symptoms
Anhedonia
Genetic profile
Dopamine
PET

ABSTRACT

Deficits in central, subcortical dopamine (DA) signaling may underlie negative symptom severity, particularly anhedonia, in healthy individuals and in schizophrenia. To investigate these relationships, we assessed negative symptoms with the Schedule for the Assessment of Negative Symptoms and the Brief Negative Symptom Scale (BNSS) and self-reported anhedonia with the Scales for Physical and Social Anhedonia (SPSA), Temporal Experience of Pleasure Scale, and Snaith-Hamilton Pleasure Scale in 36 healthy controls (HC), 27 siblings (SIB) of individuals with schizophrenia, and 66 individuals with schizophrenia or schizoaffective disorder (SCZ). A subset of participants (N = 124) were genotyped for DA-related polymorphisms in genes for DRD4, DRD2/ANKK1, DAT1, and COMT, which were used to construct biologically-informed multi-locus genetic profile (MGP) scores reflective of subcortical dopaminergic signaling. DA receptor type 2 (D2R) binding was assessed among a second subset of participants (N = 23) using PET scans with the D2R-selective, non-displaceable radioligand ([N-[^11]C]methyl)benperidol. Higher MGP scores, reflecting elevated subcortical dopaminergic signaling capacity, were associated with less negative symptom severity, as measured by the BNSS, across all participants. In addition, higher striatal D2R binding was associated with less physical and social anhedonia, as measured by the SPSA, across HC, SIB, and SCZ. The current preliminary findings support the hypothesis that subcortical DA function may contribute to negative symptom severity and self-reported anhedonia, independent of diagnostic status.

1. Introduction

The etiology of schizophrenia remains unclear but central dopamine (DA) transmission likely plays a role in its manifestation. Positive symptoms may be due in part to mesostriatal DA dysfunction (Brisch et al., 2014; Howes and Nour, 2016; Kapur, 2003), characterized by elevated striatal DA synthesis capacity and synaptic DA availability (Howes et al., 2012; Laruelle et al., 1999; Reith et al., 1994) which may in turn confer aberrant incentive salience onto non-relevant stimuli (Heinz, 2002; Robinson and Berridge, 1993; Schultz et al., 1997). By contrast, negative symptoms are posited to arise in part from hypodopaminergic transmission in prefrontal cortex (Davis et al., 1991; Goghari et al., 2010; Heinz, 2002; Knable and Weinberger, 1997). In addition, fMRI studies have shown that negative symptoms, especially those in the...
motivational dimension such as anhedonia, relate to blunted blood oxygen level-dependent (BOLD) reward-related activation in striatum among patients (Dowd and Barch, 2010, 2012; Juckel et al., 2006b; Simon et al., 2010; Waltz et al., 2009, 2010) and healthy individuals (Corral-Frias et al., 2015). Negative symptoms may also be risk factors for depression (Kuperberg et al., 2016) and substance abuse (Leventhal et al., 2010) in healthy individuals. The role of striatal DA transmission in negative symptom severity therefore merits further investigation.

The study of DA-related genetic polymorphisms may aid in understanding the role of DA signaling in both positive and negative symptom severity in schizophrenia. The disease is 80–85% heritable (Cardno and Gottesman, 2000) and common DA-related polymorphisms have been associated with variability in DA signaling (Aghari et al., 1995; Gluskin and Mickey, 2016; Heinz et al., 2000; Meyer-Lindenberg et al., 2005; Thompson et al., 1997). DA-related multilocus genetic profiles (MGPs) are composites of several DA-related polymorphisms and putatively predict ‘net’ DA function. Such DA-related MGPs have been associated with striatal BOLD responsivity to reward (Nikolova et al., 2011; Stice et al., 2012), addictive behavior and personality (Davis and Loxton, 2013), food addiction, emotional and hedonic eating (Davis et al., 2013), and depression (Pearson-Fuhrhop et al., 2014). To our knowledge, MGPs have not yet been used to study the role of subcortical DA signaling in symptom severity in schizophrenia or in healthy individuals.

Investigation of striatal D2 receptors (D2R) may yield further insight into the link between symptom severity and striatal DA function. Some studies have found increased striatal D2/D3 receptor (D2/D3R) availability in schizophrenia compared to non-diseased individuals but many others have not (Howes et al., 2012). Alternatively, symptom severity may more strongly relate to D2/D3R availability than patient status. Low striatal D2/D3R availability in patients, either at baseline or due to receptor occupancy by antipsychotics, has been associated with greater negative symptom severity (de Haan et al., 2000; Heinz et al., 1998; Lataster et al., 2011; Martinot et al., 1994; Pickar et al., 1996; Uchida et al., 2009) and dysphoria (Mizrahi et al., 2007). However, it has also been associated with greater positive and less negative symptom severity (Pogarell et al., 2012) and some studies did not show any relationship (Agid et al., 2007; Graff-Guerrero et al., 2009; Kegeles et al., 2008; Klemm et al., 1996; Talvik et al., 2006). Some of the variability in these findings may be due to certain properties of the D2/D3R radioligands used (i.e. [11C]raclopride, [123I]iodobenzamide). First, these radioligands do not distinguish between D2R and D3R (Elsinga et al., 2006; Mukherjee et al., 1999; Videbaek et al., 2000). While their distribution overlaps, these receptor subtypes are preferentially localized to different brain regions. Therefore, D2R and D3R may have distinct functional roles in symptom severity. Second, these radioligands are vulnerable to displacement by endogenous DA (Dewey et al., 1992; Laruelle et al., 1995; Riccardi et al., 2006), confounding interpretation of PET measures of in vivo D2/D3R availability. The relationship between symptom severity and striatal D2R using a non-displaceable, D2R-selective PET radioligand has not yet been studied in individuals with schizophrenia or in healthy individuals.

Here, we studied positive and negative symptom severity, with an emphasis on self-reported anhedonia, in healthy controls (HC), siblings of individuals with schizophrenia (SIB), and individuals with schizophrenia or schizoaffective disorder (SCZ). Unaffected siblings provide the opportunity to study relationships among variables of interest in individuals who share genes with their affected siblings but are medication-naive. First, we tested the hypothesis that MGP scores, which were composites of DA-related genotypes and formulated to reflect genetically regulated subcortical DA signaling capacity (Stice et al., 2012), would relate to symptom severity and self-reported anhedonia. Specifically, based on evidence of striatal hyperdopaminergic signaling in schizophrenia (Howes et al., 2012; Laruelle et al., 1999; Reith et al., 1994) and a lack of direct evidence for striatal hypodopaminergic signaling in association with symptom severity, we hypothesized that lower MGP scores that reflect lower subcortical DA signaling capacity would relate to lower levels of both positive and negative symptom severity and less self-reported anhedonia across HC, SIB, and SCZ. Second, using a novel D2R-selective PET radioligand that is not displaceable by endogenous DA, (N-[11C][methy]lpenedipirin ([11C]NMB), we tested the hypothesis that lower striatal D2R specific binding would relate to lower symptom severity and less self-reported anhedonia in a subset of HC, SIB, and unmedicated SCZ.

2. Material and methods

2.1. Participants

Participants (N = 129) aged 18–50 years, including HC (n = 36), SIB (n = 27), and SCZ (n = 66), were recruited by word of mouth, flyers, and during visits to clinics and mental health centers in St. Louis, MO (Table 1). In the whole sample, there were 12 pairs of related SIB and SCZ and 2 pair of SIB who were siblings of each other. All participants provided symptom severity and self-reported anhedonia data. Most participants provided saliva samples for genotyping (34 HC, 25 SIB, 65 SCZ; Table 2) and some completed [11C]NMB PET scans (10 HC, 10 SIB, 3 SCZ (unmedicated for ≥9 months at time of PET and unmedicated during clinical interview); 5 of whom were not genotyped (2 HC, 2 SIB, and 1 SCZ). Of the individuals who were genotyped, there were 12 pairs of related SIB and SCZ and 1 pair of SIB who were siblings of each other. Two of the SIB who underwent PET scans were siblings of each other. Fifty five SCZ were taking antipsychotic medications at the time of screening. We converted antipsychotic medication doses to 100 mg chlorpromazine equivalents (Lehman et al., 2004 for Loxapine calculation only); Leucht et al., 2014).

After the study procedures were fully explained, all participants provided written informed consent prior to participation. The study protocol was approved by the Washington University School of Medicine Human Research Protection Office and the Radioactive Drug Research Committee, and was carried out in accordance with the principles expressed in the Declaration of Helsinki. Exclusion criteria are described in Supplementary Information 1.

2.2. Symptom severity and anhedonia assessment

During the screening day, a trained research assistant administered the Structured Clinical Interview for the DSM-IV (First et al., 2002) to determine the lifetime and current history of Axis I disorders and obtain basic demographic information (Table 1). To assess symptom severity, the Schedule for the Assessment of Negative Symptoms (SANS) (Andreasen, 1983a, Schedule for the Assessment of Positive Symptoms (SAPS) (Andreasen, 1983b), and the Brief Negative Symptom Scale (BNSS) (Kirkpatrick et al., 2011) were administered. Participants completed self-report scales including the Scales for Physical and Social Anhedonia (SPSA) (Chapman et al., 1976), Snith-Hamilton Pleasure Scale (SHAPS) (Snith et al., 1995) and Temporal Experience of Pleasure Scale (TEPS) (Gard et al., 2006) to assess hedonic capacity as well as the Wechsler Adult Intelligence Scale vocabulary and matrix reasoning subtests to assess intellectual functioning (WAIS 4th Edition (Wechsler, 2008)).
2.3. Genotyping

Participants provided saliva on a voluntary basis with an Ora
saliva kit (www.dnagenotek.com). Following DNA extraction
and quantitation normalization, the following polymorphisms
were genotyped by the Molecular Psychiatry Core at Washington
University in St. Louis School of Medicine by pyrosequencing:
DRD2/ANKK1 TaqIA (rs1800497), SLC6A3 (DAT1) 10R/10R
polymorphisms shown in bold denote a statistically signifi-
cant difference among groups.

Table 2

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Allele set</th>
<th>N</th>
<th>Gender distribution</th>
<th>Ethnicity distribution</th>
<th>Group distribution</th>
<th>DA signaling capacity (score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TaqIAa</td>
<td>A1/A1</td>
<td>10</td>
<td>5 F/5 M</td>
<td>0 EA, 9 AA, 1 multi</td>
<td>1 HC, 1 Sib, 8 SCZ</td>
<td>Low (1)</td>
</tr>
<tr>
<td></td>
<td>A1/A2</td>
<td>47</td>
<td>26 F/21 M</td>
<td>19 EA, 25 AA, 2 As, 1 Al*</td>
<td>16 HC, 8 Sib, 23 SCZ</td>
<td>Intermediate (1.5)</td>
</tr>
<tr>
<td></td>
<td>A2/A2</td>
<td>67</td>
<td>30 F/37 M</td>
<td>32 EA, 32 AA, 2 multi, 1 Al***</td>
<td>17 HC, 16 Sib, 34 SCZ</td>
<td>High (2)</td>
</tr>
<tr>
<td>COMT val158metb</td>
<td>met/met</td>
<td>27</td>
<td>13 F/16 M</td>
<td>17 EA, 8 AA, 1As, 1 Multi</td>
<td>5 HC, 6 Sib, 16 SCZ</td>
<td>Low (1)</td>
</tr>
<tr>
<td></td>
<td>met/val</td>
<td>48</td>
<td>24 F/24 M</td>
<td>16 EA, 30 AA, 1 Al, 1 multi**</td>
<td>14 HC, 9 Sib, 25 SCZ</td>
<td>Intermediate (1.5)</td>
</tr>
<tr>
<td></td>
<td>val/val</td>
<td>49</td>
<td>24 F/25 M</td>
<td>18 EA, 28 AA, 1 As, 1 Al, 1 multi*</td>
<td>15 HC, 30 Sib, 24 SCZ</td>
<td>High (2)</td>
</tr>
<tr>
<td>DRD4</td>
<td>Repeats ≥ 7</td>
<td>51</td>
<td>26 F/25 M</td>
<td>21 EA, 27 AA, 1 As, 1 Al, 1 Multi</td>
<td>14 HC, 9 Sib, 28 SCZ</td>
<td>Low (1)</td>
</tr>
<tr>
<td></td>
<td>Repeats &lt; 7</td>
<td>73</td>
<td>35 F/38 M</td>
<td>30 EA, 39 AA, 1 As, 1 Al, 1 Multi</td>
<td>20 HC, 16 Sib, 37 SCZ</td>
<td>High (2)</td>
</tr>
<tr>
<td>SLC6A3 (DAT1)</td>
<td>10R/10R</td>
<td>68</td>
<td>35 F/33 M</td>
<td>26 EA, 36 AA, 2 As, 1 Al, 3 Multi</td>
<td>21 HC, 10 Sib, 37 SCZ</td>
<td>Low (1)</td>
</tr>
<tr>
<td></td>
<td>9R/X</td>
<td>56</td>
<td>26 F/30 M</td>
<td>25 EA, 30 AA, 1 Al</td>
<td>13 HC, 15 Sib, 28 SCZ</td>
<td>High (2)</td>
</tr>
</tbody>
</table>

Abbreviations: DA, dopamine; F, female; M, male; EA, European American; AA, African American; multi, multiracial; As, Asian; AI, American Indian; HC, healthy control; SIB, sibling; SCZ, individual with schizophrenia. *Results of a univariate analysis of variance followed by Tukey's LSD post hoc tests. **, ***p ≤ 0.05, 0.01, 0.001 relative to healthy control group; ****p ≤ 0.01, 0.001 relative to healthy control group; p < 0.10 relative to sibling group; p = 0.09 relative to healthy control group. p-values shown in bold denote a statistically significant difference among groups.
results excluding COMT \text{val}^{158}\text{met} rs4680 from our MGP score in Supplementary Information 2.

2.4. Multilocus genetic profile scoring

MGP scores were assigned to each individual by assigning scores to allele pairs for each of 4 polymorphisms similar to the method used by Stice et al. (2012). The \text{DRD2/ANKK1 TaqA (rs1800497)} A2 allele is associated with greater striatal D2R binding relative to the A1 allele (Eisenstein et al., 2016; Gluskin and Mickey, 2016). The \text{COMT (rs4680)} val allele may be associated with lower amounts of tonic DA transmission in cortical regions due to greater COMT activity, but it is thought to confer greater phasic DA transmission in striatum and other subcortical regions due to reduced tonic auto-inhibition relative to met/met (Bilder et al., 2004). The \text{DRD4} bp 3 7-repeat variant is associated with reduced dopamine-mediated inhibition of cyclic AMP formation relative to \text{DRD4} repeats <7 (Ashgari et al., 1995). Finally, individuals with the 9-repeat allele of \text{SLC6A3 DAT1} have higher DAT expression compared to individuals homozygous for the 10-repeat allele (van de Giessen et al., 2005; van Dyck et al., 2005). In contrast to Stice et al. (2012), individuals homozygous or heterozygous for the \text{SLC6A3 DAT1} 9-repeat allele were assigned the high score as in Nikolova et al. (2011), and in Davis et al. (Davis and Loxton, 2013; Davis et al., 2013). In addition, we did not genotype participants for the \text{DRD2-141C Ins/Del polymorphism}; therefore, the MGP formula did not include scores for these alleles. Scores were summed such that higher MGP scores indicated higher DA signaling capacity (Table 2).

2.5. MRI and PET acquisition, preprocessing, and analyses

MRI and PET data were acquired a mean of 14 months (S.D. = 11.5) after completion of the symptom severity and anhedonia measures in HC, SIB, and unmedicated SCZ. Simultaneous radioligand \text{[11C]NMB} PET and structural MR T1-weighted anatomical images were obtained with a Siemens Biograph mMR PET/MR scanner (Delso et al., 2011) using a 3-D MP-RAGE sequence (sagittal orientation, TR = 2400 ms, TE = 2.67 ms, flip angle = 7°, slab thickness = 192 mm, FOV = 256 × 256 mm; voxel dimensions = 1 × 1 × 1 mm). \text{[11C]NMB}, was prepared using an automated system previously described (Moorleijn et al., 2004, 2010). Radiochemical purity of \text{[11C]NMB} was >95% and specific activity was ≥961 Ci/mmol (36 TBq/mmol). Injected dose of unlabeled NMB was ≤179 μg. Participants received 5.9–18.8 mCi \text{[11C]NMB} intravenously. Emission data were collected in 3D mode for 30 frames: 3 × 1 min, 4 × 2 min, 3 × 3 min and 20 × 5 min. Attenuation correction was MR-based (Delso et al., 2011).

MR and PET image processing was previously described in detail (Eisenstein et al., 2012, 2013). A priori regions of interest (ROIs) including dorsal (putamen + caudate) and ventral (nucleus accumbens (NAc)) areas of the striatum were identified using FreeSurfer (Fischl et al., 2002) on the MP-RAGE MR images for each participant. Dynamic PET images were aligned to each other and then co-registered to the MP-RAGE image for each individual as previously described (Eisenstein et al., 2012). ROIs and the cerebellar reference region were resampled in the same atlas space (Hershey et al., 2003). Decay-corrected tissue activity curves were obtained from the dynamic PET data. D2R non-displaceable binding potentials (BP_{ND}) were obtained for each ROI using the Logan graphical method with whole cerebellum as a reference region (Antenor-Dorsey et al., 2008). D2R BP_{ND} for each ROI were averaged across left and right hemispheres to reduce the number of comparisons for primary analyses. We recently published a report within this sample linking D2R binding to \text{DRD2/ANKK1 TaqA (rs1800497)} genotype (Eisenstein et al., 2016).

2.6. Primary data analyses

Demographic variables were tested for differences among groups with Kruskal-Wallis \text{H} tests. Differences between groups in gender and ethnicity distributions, symptom severity, self-reported anhedonia, MGP scores, and D2R binding were assessed with univariate analyses of variance followed by Tukey’s LSD post hoc tests. To eliminate Type I error inflation due to relatedness, genetic analyses (those including MGP scores as predictor variables) were performed on a sample in which data from one sibling of each sibling pair (6 SIB, 7 SCZ) was randomly removed, resulting in a total sample size of \( N = 111 \) unrelated individuals (34 HC, 19 SIB, 58 SCZ). Prediction of outcome variables by centered MGP scores were then assessed with hierarchical multiple linear regression (HMLR) models; covariates (age, gender, ethnicity, scaled WAIS score, and education) were included in step 1, diagnostic group (HC vs. SIB vs. SCZ) was included in step 2, MGP scores were included in step 3, and the diagnostic group x MGP scores interaction was entered in step 4. In complementary analyses that included the full sample (\( N = 124 \)), a random effects model (REM) implemented using PROC MIXED in SAS 9.4 (SAS Institute, Cary, NC) was applied to assess prediction of study variable outcomes by MGP scores accounting for correlations of outcome variables from the same family. Multivariate REMs with group and MGP score considering age, gender, ethnicity and number of years of education were constructed via a forward selection procedure. This procedure takes into account all factors where \( p < 0.3 \) in the univariate analyses and the significance level for entering factors was set at 0.1. Residual plots from the models were used to assess the normality assumption of errors. Predictions of study variables by D2R binding was assessed using HMLR; covariates (diagnostic group, age at time of PET, age at time of clinical interview, gender, ethnicity, WAIS scaled score, and education) were included in step 1, and D2R binding was included in step 2. REMs were not performed for analyses including D2R binding because these included data from only two related SIB individuals. When MGP scores or D2R binding significantly predicted total scores on a scale that served as a dependent variable (i.e. BNSS), follow-up HMLRs were performed to determine if MGP or D2R binding related to scores on subscales (i.e. alogia) of that scale. For primary HMLR analyses regarding symptom severity (3 scales) and anhedonia (3 scales), resulting \( p \)-values were corrected for multiple comparisons using the Bonferroni method such that \( p \leq 0.008 \) was considered statistically significant (0.05/6 scales). Otherwise, results were considered significant at \( p \leq 0.05 \).

3. Results

3.1. Sample description

See Table 1 for descriptive statistics. In the genotyped sample, diagnostic groups did not differ in mean urine cotinine levels or gender and ethnicity distributions. However, SIB were significantly younger, had more education, and higher WAIS scores than SCZ. Among the subset of individuals that underwent PET scans, SCZ were less educated than SIB but otherwise there were no significant group differences. SCZ antipsychotic medications included Arapiprazole, Clozapine, Haloperidol, Loperidone, Loxipine, Olanzapine, Paliperidone, Risperidone, Quetiapine, and Ziprasidone. Dosage data was missing for 3 individuals. Eleven SCZ, including n = 3 who underwent PET, were not medicated. The mean (S.D.) 100 mg chlorpromazine equivalent was 723.5 mg (597.7) (range = 125–3333 mg). For genotype distribution among ethnic groups differed for \text{DRD2/ANKK1 TaqA (rs1800497); F2,121 = 4.3, p = 0.02) and COMT val^{158}\text{met (rs4680); univariate ANOVA F2,121 = 3.6, p = 0.03, Table 2}. Total MGP scores, however, did not differ between European American (mean
Pearson indicated that higher MGP scores predicted lower BNSS scores for correlation of outcome variables from the same family also self-reported anhedonia as measured by the SPSA but this than HC and SIB (Table 1). Elevated MGP scores, reflecting higher subcortical DA signaling capacity, were associated with reduced negative symptom severity as measured by the BNSS across HC, SIB, and SCZ (\( r_{111} = -0.28, p = 0.004, \Delta R^2 = 0.04 \); Fig. 1, Supplementary Table 2). The magnitude of this relationship was larger when only African Americans were included in the analysis (\( r_{62} = -0.33, p = 0.01, \Delta R^2 = 0.06 \)) but smaller when only European Americans were included (\( r_{42} = -0.22, p = 0.19, \Delta R^2 = 0.03 \)). Post-hoc analyses of BNSS subscales revealed that elevated MGP scores related to lower Anhedonia (\( r_{111} = -0.21, p = 0.04 \)), Avolition (\( r_{111} = -0.20, p = 0.04 \)), Distress (\( r_{111} = -0.23, p = 0.02 \)) and Alogia (\( r_{111} = -0.22, p = 0.03 \)) but not Asociality (\( r_{111} = -0.17, p = 0.09 \)) scores on subscales of the BNSS. MGP scores were more strongly associated with BNSS scores than individual DA-related SNPs or VNTRs (Supplementary Table 3). When separate analyses replaced the total MGP score with one calculated by summing allele scores and ‘leaving out’ contribution from one of the SNPs, results further indicated that no single loci drove the association between MGP and BNSS scores (associations remained significant or near-significant regardless of which SNP was ‘left out’; Supplementary Table 3). REM analyses that accounted for correlation of outcome variables from the same family also indicated that higher MGP scores predicted lower BNSS scores (Pearson \( r_{124} = -0.20, \) REM \( p = 0.05 \)) across HC, SIB, and SCZ. MGP scores did not relate to negative or positive symptom severity as measured by the SANS (HMLR: \( r_{111} = -0.09, p = 0.35 \); Pearson \( r_{124} = -0.07, \) REM \( p = 0.87 \)) or the SAPS (HMLR: \( r_{111} = -0.13, p = 0.20 \); Pearson \( r_{124} = -0.09, \) REM \( p = 0.77 \)), respectively. There were no diagnostic group \times MGP interactions for symptom severity (all \( p \geq 0.27 \)).

### 3.2. MGP scores and symptom severity

Unsurprisingly, SCZ reported higher symptom severity scores across measures (BNSS, SANS, SAPS) than HC and SIB (Table 1). MGP scores did not differ between groups (Table 1). Elevated MGP scores, reflecting higher subcortical DA signaling capacity, were associated with reduced negative symptom severity as measured by the BNSS across HC, SIB, and SCZ (\( r_{111} = -0.28, p = 0.004, \Delta R^2 = 0.04 \); Fig. 1, Supplementary Table 2). The magnitude of this relationship was larger when only African Americans were included in the analysis (\( r_{62} = -0.33, p = 0.01, \Delta R^2 = 0.06 \)) but smaller when only European Americans were included (\( r_{42} = -0.22, p = 0.19, \Delta R^2 = 0.03 \)). Post-hoc analyses of BNSS subscales revealed that elevated MGP scores related to lower Anhedonia (\( r_{111} = -0.21, p = 0.04 \)), Avolition (\( r_{111} = -0.20, p = 0.04 \)), Distress (\( r_{111} = -0.23, p = 0.02 \)) and Alogia (\( r_{111} = -0.22, p = 0.03 \)) but not Asociality (\( r_{111} = -0.17, p = 0.09 \)) scores on subscales of the BNSS. MGP scores were more strongly associated with BNSS scores than individual DA-related SNPs or VNTRs (Supplementary Table 3). When separate analyses replaced the total MGP score with one calculated by summing allele scores and ‘leaving out’ contribution from one of the SNPs, results further indicated that no single loci drove the association between MGP and BNSS scores (associations remained significant or near-significant regardless of which SNP was ‘left out’; Supplementary Table 3). REM analyses that accounted for correlation of outcome variables from the same family also indicated that higher MGP scores predicted lower BNSS scores (Pearson \( r_{124} = -0.20, \) REM \( p = 0.05 \)) across HC, SIB, and SCZ. MGP scores did not relate to negative or positive symptom severity as measured by the SANS (HMLR: \( r_{111} = -0.09, p = 0.35 \); Pearson \( r_{124} = -0.07, \) REM \( p = 0.87 \)) or the SAPS (HMLR: \( r_{111} = -0.13, p = 0.20 \); Pearson \( r_{124} = -0.09, \) REM \( p = 0.77 \)), respectively. There were no diagnostic group \times MGP interactions for symptom severity (all \( p \geq 0.27 \)).

### 3.3. MGP scores and self-reported anhedonia

Overall, SCZ had significantly greater self-reported anhedonia than HC and SIB (Table 1). Elevated MGP scores related to lower self-reported anhedonia as measured by the SPSA but this finding did not survive multiple comparisons correction (HMLR: \( r_{111} = -0.20, p = 0.04, \Delta R^2 = 0.03 \); Pearson \( r_{124} = -0.16, \) REM \( p = 0.18 \)). MGP scores did not correlate with hedonic capacity as measured by SHAPS (HMLR: \( r_{111} = -0.07, p = 0.51 \); Pearson \( r_{124} = -0.06, \) REM \( p = 0.30 \)) or TEPS (HMLR: \( r_{111} = 0.08, p = 0.42 \); Pearson \( r_{124} = 0.09, \) REM \( p = 0.42 \)). There were no diagnostic group \times MGP interactions for anhedonia severity (all \( p \geq 0.24 \)).

Analyses including MGP scores not including COMT, which was not in HWE for the full sample, are presented in Supplementary Information 2. These results are similar in magnitude and direction to the results reported above.

### 3.4. Striatal D2R binding and symptom severity

For each symptom severity measure (BNSS, SANS, SAPS), SCZ had significantly higher scores than HC and SIB (Table 1). D2R BPND did not differ between groups (Table 1). Dorsal striatal D2R BPND was negatively correlated with SANS scores at trend-level significance (\( r_{23} = -0.45, p = 0.08, \Delta R^2 = 0.07 \)). NAc D2R BPND did not relate to SANS scores \( r_{23} = -0.38, p = 0.15 \). Neither dorsal striatal nor NAc D2R BPND was associated with negative symptom severity as measured by the BNSS (both ROIs: \( r_{23} \geq -0.28, p > 0.29 \)), or positive symptom severity as measured by the SAPS (both ROIs: \( r_{23} \geq -0.07, p \geq 0.80 \)).

### 3.5. Striatal D2R binding and self-reported anhedonia

Self-reported anhedonia did not differ among groups (Table 1). Elevated dorsal striatal D2R BPND significantly predicted lower anhedonia as measured by the SPSA \( r_{23} = -0.70, p = 0.003, \Delta R^2 = 0.28 \); Fig. 2, Supplementary Table 4). This relationship remained even when excluding SCZ \( r_{20} = -0.69, p = 0.009, \Delta R^2 = 0.26 \) and when excluding the related SIB \( r_{21} = -0.64, p = 0.01, \Delta R^2 = 0.21 \) from the analyses. Specifically, in the whole sample, greater dorsal striatal D2R BPND related to both lower physical anhedonia \( r_{23} = -0.56, p = 0.02, \Delta R^2 = 0.19 \) and social anhedonia \( r_{23} = -0.69, p = 0.003, \Delta R^2 = 0.29 \). NAc D2R BPND predicted anhedonia as measured by the SPSS at a significance level that did not survive multiple comparisons correction \( r_{23} = -0.57, p = 0.02, \Delta R^2 = 0.19 \). Neither dorsal striatal nor NAc D2R BPND were associated with SHAPS (both ROIs: \( r_{23} \geq -0.30, p \geq 0.26 \)) or TEPS \( r_{23} \leq 0.21, p \geq 0.43 \) scores.

### 3.6. Striatal D2R binding and MGP scores

Consistent with our previous report linking the DRD2/ANKK1

---

**Fig. 1.** Greater DA signaling capacity, as reflected by MGP scores, was related to lower negative symptom severity as measured by the Brief Negative Symptom scale (BNSS) across diagnostic groups. HC, healthy control; SIB, sibling of individual with schizophrenia; SCZ, individual diagnosed with schizophrenia or schizoaffective disorder; MGP, multilocus genetic profile.

**Fig. 2.** Lower D2R binding in dorsal striatum was associated with greater self-reported anhedonia as measured by the Scales for Physical and Social Anhedonia (SPSA) across diagnostic groups. HC, healthy control; SIB, sibling of individual with schizophrenia; SCZ, individual diagnosed with schizophrenia or schizoaffective disorder; D2R, dopamine D2 receptor; BPND, non-displaceable binding potential.
rs1800497 to D2R in this sample (Eisenstein et al., 2016), MGP scores predicted dorsal striatal (r18 = 0.65, p = 0.02) but not NAc D2R BPND (r18 = 0.46, p = 0.11). At the individual SNP/VNTR level, the DRD2/ANKK1 rs1800497 polymorphism significantly related to dorsal striatal D2R BPND, as previously reported (Eisenstein et al., 2016). None of the other polymorphism tested (COMT rs4680, SLC6A3 DAT1, DRD4 exon 3 48 bp) predicted dorsal striatal D2R binding (all r ≤ 0.47, p ≥ 0.10). However, D2R binding was still predicted by the MGP score when the DRD2/ANKK1 rs1800497 polymorphism was excluded from the calculation (r18 = 0.55, p = 0.05).

4. Discussion

Contrary to our hypotheses, elevated subcortical DA signaling capacity, reflected by higher MGP scores, predicted lower negative symptom severity as measured by the BNSS, and, at a level that did not survive multiple comparisons correction, lower self-reported anhedonia as measured by the SPSA across HC, SIB, and SCZ. Our results add to existing PET/SPECT (de Haan et al., 2000; Heinz et al., 1998; Lataster et al., 2011; Martinot et al., 1994; Pickar et al., 1996; Uchida et al., 2009; Voruganti et al., 2001; Voruganti and Awad, 2006) and fMRI (Dowd and Barch, 2010, 2012; Caldersi et al., 2015; Goghari et al., 2010; Juckel et al., 2006a; Simon et al., 2010; Strauss et al., 2014; Waltz et al., 2009, 2010) evidence that negative symptom severity relates to altered subcortical DA signaling and striatal reactivity, respectively. Our findings are also in line with those of other studies in which genetic profile scores reflecting high DA signaling capacity relate to increased brain responsivity to reward (Nikolova et al., 2011; Stice et al., 2012) and lower depressive symptom severity (Pearson-Fuhrhop et al., 2014). By contrast, we did not observe a relationship between MGP and SANS scores. The BNSS differs from the SANS in that, besides requiring shorter administration time, it differentiates consummatory from anticipatory pleasure, has a Distress subscale, and has separate items for measuring facial expression, vocal expression, and expressive gestures (Daniel, 2013). Given that, in our study, higher MGP scores related to anhedonia, as measured by the Anhedonia subscale, lack of normal distress, as measured by the Distress subscale, and poverty of speech, as measured by the Alogia subscale, these differences between scales are a potential reason for our limited ability to detect a relationship between DA signaling capacity and negative symptom severity as measured by the SANS. Future studies may aim to replicate our results, which should be viewed as preliminary due to small sample sizes, the small number of genes used in the MGP formula, and differences in genetic distributions between ethnic groups.

We did not observe a relationship between positive SAPS-measured symptom severity and subcortical DA signaling capacity as reflected by MGP scores. This is surprising since hyperdopaminergic function in the mesolimbic pathway may underlie positive symptoms in schizophrenia (Davis et al., 1991). However, most SCZ were medicated and variability in positive symptom severity may have been masked in these individuals. It is also possible that SNPs related to presynaptic aspects of DA signaling would better predict positive symptom severity than an MGP score that may reflect overall subcortical DA signaling capacity.

Also contrary to our hypotheses, higher dorsal striatal D2R binding, as measured by PET with [11C]NMB, was associated with less self-reported anhedonia, as measured by the SPSA, and, at a near-significant level, less negative symptom severity as measured by the SANS across diagnostic groups. This relationship remained intact when SCZ were removed from the analysis. Our finding is in line with those in which D2R pharmacological blockade or genetic knockout caused reward-related behavior deficits (Elmer et al., 2005; Wise, 1978) and D2/D3R agonism reversed anhedonia (Willner et al., 1994) in rodents. Also consistent with our results, human pharmacological studies show that anhedonia is attenuated by chronic D2/D3R agonism in Parkinson disease (Lemke et al., 2006) and chronic, partial D2R agonism in schizophrenia (Liemburg et al., 2011). Finally, greater striatal D2/D3R occupancy with antipsychotics relates to dysphoria in patients (Mizrahi et al., 2007) and antipsychotic use induces dysphoria in healthy individuals (King et al., 1995). Of note, DA receptor sensitivity is positively related to affective flattening, but not anhedonia per se, in depressed patients (Schmidt et al., 2001). However, unlike the current and previous human studies described, the Schmidt et al. (2001) study did not distinguish between D1- and D2-type receptors. In summary, the current preliminary result, which must be confirmed by future replication studies, supports the hypothesis that anhedonia is in part due to low D2R function (Heinz et al., 1994; Wise, 1982).

MGP scores predicted dorsal striatal D2R binding as measured by PET. We have previously shown, in this same sample, that DRD2/ANKK1 TaqIA A1 allele carriers had lower dorsal striatal D2R specific binding relative to individuals homozygous for A2 (Eisenstein et al., 2016). The presence of this relationship in this sample lends support to the use of [11C]NMB as a valid PET radioligand to measure D2R binding. Unfortunately, we did not have the statistical power (n = 15 participants with PET and genetic data) to test whether D2R binding mediated the relationship between MGP scores and self-reported anhedonia.

The current study has limitations. First, the sample size was small and precluded reliable analysis of genotype frequencies in small ethnic subgroups and reported associations should be interpreted with caution until replicated. Second, the PET radioligand used, [11C]NMB, due to its selectivity for D2R over D3R, is not optimal for measuring D2R in NAc since it contains fewer D2R than dorsal striatal regions, causing increased variability in D2R BPND measurements (Eisenstein et al., 2012). We were likely unable to detect strong relationships between ventral striatum and other variables for this reason. However, greater NAc D2R did relate to less self-rated anhedonia, as measured by the SPSA, at a significance level that did not pass multiple comparisons correction. For similar reasons, we did not examine D2R binding in the prefrontal cortex, which would have been interesting given its association with negative symptoms (Davis et al., 1991; Goghari et al., 2010; Knable and Weinberger, 1997). Third, we did not have statistical power to investigate the impact of smoking severity or antipsychotic medication use on the relationships between MGP scores or striatal D2R binding and negative symptoms. Fourth, for some participants, there was a considerable length of time between completion of anhedonia self-report questionnaires and PET measurement of striatal D2R binding. However, previous research indicates high test-retest reliability for trait anhedonia in patients and controls over 90 days (Blanchard et al., 1998), 1 year (Blanchard et al., 2001), and 10 years (Hembener and Harrow, 2002). Fifth, the relationships between MGP scores or D2R binding and negative symptom severity did not hold across all measures. Although moderate to high correlations in the expected directions were observed between SANS and BNSS scores and between SPSA, SHAPS, and TEPS scores (data not shown), subtle differences in aspects of negative symptom severity and self-reported anhedonia that are measured by each scale and/or low statistical power to detect these relationships may have contributed to our null findings. Future studies should include larger samples and control for ethnicity to avoid these kinds of limitations. Finally, MR-based attenuation correction may bias PET activity measurements such that it is underestimated in most of the brain and overestimated in deep brain regions compared to CT-based attenuation maps (Su
et al., 2016). Since the bias does not appear to affect clinical assessment and PET activities after both MR- and CT-based attenuation methods are closely correlated (Su et al., 2016), it should not have affected our results in a way that changes their interpretation. In the future, CT-based attenuation correction may be implemented to obtain more accurate PET activity measurements from hybrid PET/MR scanners.

In summary, the current study shows that subcortical DA signaling capacity, as reflected by MGP scores, and dorsal striatal D2R binding correlated with clinician-rated and self-reported negative symptom severity across HC, SIB and SCZ. These pre- liminary results support the notion that striatal DA signaling contributes to negative symptoms, including anhedonia, thereby serving as a potential pharmacotherapeutic target in psychiatric diseases including schizophrenia and depression.

Author contributions

SAE, RB, and DMB wrote the manuscript. SAE and LC analyzed data. SAE, RB, DMB, KJB, JSP, and TH contributed to study design and methods. SMM contributed reagents. All authors reviewed and edited the manuscript.

Role of funding source

This research was funded by a NARSAD Young Investigator Award (SAE); a McDonnell Center for Systems Neuroscience New Resource Proposal (SAE); Gregory B. Couch Award (DMB); Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund) (JSP); and the National Institutes of Health [UL1 TR000448, R01 MH066031 (DMB), R01 AG045231 (RB)]. RB receives support from the Klingen- stein Third Generation Foundation. This study was supported in part by the Neuroimaging Informatics and Analysis Center (1P30NS098577). This publication was made possible by Grant Number UL1 RR024992 (LC) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. These funding sources had no further role in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.

Conflict of interest

KJB: ACADIA Pharmaceuticals (advisory board, speakers bureau, research funding). Auspex Pharmaceuticals (consultant). Psyadon, Inc. (research funding), Neurocine Biosciences, Inc. (research funding), and U. S. patent # 8,463,552 and patent application # 13/ 890,198.

DMB: Roche (consultant), Takeda Pharmaceuticals U.S.A., Inc. (consultant), Pfizer (consultant), Amgen (consultant).

Acknowledgements

The studies presented in this work were conducted using the Center for Clinical Imaging Research located at the Washington University Medical Center. We thank Jonathan M. Koller, B.S. for his help with PET/MR processing. We thank Melissa Cornejo, Arthur Schaffer, and Danielle Kelly for their help with recruiting participants.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http:// dx.doi.org/10.1016/j.jpsychires.2016.11.007.

References


Andreasen, N.C., 1983a. The Scale for the Assessment of Negative Symptoms (SANS). The University of Iowa, Iowa City, Iowa.

Andreasen, N.C., 1983b. Scale for the Assessment of Positive Symptoms (SAPS). The University of Iowa, Iowa City, Iowa.


